Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BISNASDAQ:FTXHNASDAQ:JDOCNASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBISProShares UltraShort Nasdaq Biotechnology$16.73-0.9%$18.44$14.05▼$25.87$2.85M-1.4112,558 shs8,114 shsFTXHFirst Trust Nasdaq Pharmaceuticals ETF$26.31+0.0%$25.53$23.29▼$29.72$14.47M0.556,663 shs409 shsJDOCJPMorgan Healthcare Leaders ETF$50.600.0%$50.02$47.67▼$63.49$7.59M0.61353 shs92 shsZBIOZenas BioPharma$10.03-1.9%$10.23$5.83▼$26.25$427.55MN/A215,731 shs145,704 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBISProShares UltraShort Nasdaq Biotechnology-3.15%-4.31%-8.60%-14.05%-0.53%FTXHFirst Trust Nasdaq Pharmaceuticals ETF+0.86%+2.05%+2.97%-1.09%-2.48%JDOCJPMorgan Healthcare Leaders ETF0.00%+1.57%+1.21%-3.61%-12.93%ZBIOZenas BioPharma+11.82%+0.29%+1.59%+31.03%+1,021,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBISProShares UltraShort Nasdaq BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AN/AN/AN/AN/AN/AN/AN/AJDOCJPMorgan Healthcare Leaders ETFN/AN/AN/AN/AN/AN/AN/AN/AZBIOZenas BioPharma1.6664 of 5 stars3.50.00.00.02.20.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBISProShares UltraShort Nasdaq Biotechnology 0.00N/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETF 2.58Moderate Buy$26.31N/AJDOCJPMorgan Healthcare Leaders ETF 2.74Moderate Buy$50.60N/AZBIOZenas BioPharma 3.00Buy$36.67265.57% UpsideCurrent Analyst Ratings BreakdownLatest ZBIO, BIS, JDOC, and FTXH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ZBIOZenas BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/15/2025ZBIOZenas BioPharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$35.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBISProShares UltraShort Nasdaq BiotechnologyN/AN/AN/AN/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AN/AN/AN/AN/AN/AJDOCJPMorgan Healthcare Leaders ETFN/AN/AN/AN/AN/AN/AZBIOZenas BioPharma$5M83.91N/AN/A$7.48 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBISProShares UltraShort Nasdaq BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AN/A14.51∞N/AN/AN/AN/AN/AJDOCJPMorgan Healthcare Leaders ETFN/AN/A25.23∞N/AN/AN/AN/AN/AZBIOZenas BioPharma-$156.99M-$3.55N/A∞N/AN/AN/AN/A8/21/2025 (Estimated)Latest ZBIO, BIS, JDOC, and FTXH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ZBIOZenas BioPharma-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBISProShares UltraShort Nasdaq Biotechnology$0.593.53%N/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETF$0.441.67%N/AN/AN/AJDOCJPMorgan Healthcare Leaders ETF$2.815.55%N/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ALatest ZBIO, BIS, JDOC, and FTXH DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/24/2025BISProShares UltraShort Nasdaq BiotechnologyQuarterly$0.10802.45%6/25/20256/25/20257/1/20256/25/2025FTXHFirst Trust Nasdaq Pharmaceuticals ETFQuarterly$0.08921.39%6/26/20256/26/20256/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBISProShares UltraShort Nasdaq BiotechnologyN/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AN/AN/AJDOCJPMorgan Healthcare Leaders ETFN/AN/AN/AZBIOZenas BioPharmaN/A6.476.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBISProShares UltraShort Nasdaq BiotechnologyN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AJDOCJPMorgan Healthcare Leaders ETFN/AZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipBISProShares UltraShort Nasdaq BiotechnologyN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AJDOCJPMorgan Healthcare Leaders ETFN/AZBIOZenas BioPharma16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBISProShares UltraShort Nasdaq BiotechnologyN/A170,000N/AOptionableFTXHFirst Trust Nasdaq Pharmaceuticals ETF147,000550,002N/AOptionableJDOCJPMorgan Healthcare Leaders ETFN/A150,000N/AN/AZBIOZenas BioPharmaN/A41.83 million34.93 millionN/AZBIO, BIS, JDOC, and FTXH HeadlinesRecent News About These CompaniesInnovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharmaJuly 3 at 6:37 AM | tipranks.comRhumbline Advisers Sells 27,428 Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO)June 27, 2025 | marketbeat.comZenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20, 2025 | globenewswire.comZBIO DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 ...June 17, 2025 | stockhouse.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 17, 2025 | prnewswire.comInvestors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)June 16, 2025 | accessnewswire.comAZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 16, 2025 | globenewswire.comZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineJune 16, 2025 | globenewswire.comJune 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & KorsinskyJune 16, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 16, 2025 | accessnewswire.comAFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaJune 16, 2025 | businesswire.comSecurities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025June 16, 2025 | accessnewswire.comAZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 16, 2025 | prnewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Zenas BioPharma, Inc. (ZBIO) Investors of June 16, 2025 DeadlineJune 16, 2025 | accessnewswire.comAFINAL REMINDER ZBIO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Zenas BioPharma, Inc. Investors to Participate in the Class Action LawsuitJune 16, 2025 | accessnewswire.comAJune 16, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ZBIOJune 16, 2025 | prnewswire.comZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors - Lead Plaintiff Deadline June 16, 2025June 16, 2025 | accessnewswire.comAFINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIOJune 16, 2025 | prnewswire.comSecurities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025June 15, 2025 | accessnewswire.comAZBIO IMPORTANT DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by The Firm - ZBIOJune 15, 2025 | accessnewswire.comAZenas BioPharma, Inc. (ZBIO) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before June 16, 2025June 15, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseWhy Nebius Group Is One of the Top AI Stocks to WatchBy Thomas Hughes | June 17, 2025View Why Nebius Group Is One of the Top AI Stocks to WatchTop 4 Growth Stocks With Momentum and Room to RunBy Ryan Hasson | June 16, 2025View Top 4 Growth Stocks With Momentum and Room to RunZBIO, BIS, JDOC, and FTXH Company DescriptionsProShares UltraShort Nasdaq Biotechnology NASDAQ:BIS$16.73 -0.16 (-0.92%) As of 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in equity securities and derivatives that have similar daily performance characteristics as twice (200%) the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.First Trust Nasdaq Pharmaceuticals ETF NASDAQ:FTXH$26.30 +0.01 (+0.02%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.JPMorgan Healthcare Leaders ETF NASDAQ:JDOC$50.60 -0.01 (-0.02%) As of 02:20 PM EasternThe JPMorgan Healthcare Leaders ETF Healthcare Leaders ETF (JDOC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies located around the globe.The adviser seeks to provide long-term capital appreciation. JDOC was launched on Nov 1, 2023 and is issued by JPMorgan Chase.Zenas BioPharma NASDAQ:ZBIO$10.03 -0.19 (-1.86%) As of 01:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
